Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (FRA:FDY) Interest Coverage: 0 (At Loss) (As of Dec. 2025)


FRA:FDY Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd FRA:FDY
72 GF Score
Price €0.25
GF Value €0.24
! 2 Warning Signs
View Full Analysis

What is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Interest Coverage?

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co FRA:FDY -2.36% 72 Interest Coverage is 0 (At Loss) as of Dec. 2025. GuruFocus rates FRA:FDY with a GF Score™ of 72/100 and a GF Value™ of €0.24. The stock has 2 warning signs investors should review. Among 685 Drug Manufacturers companies, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co ranks worse than 145985.26% on this metric.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Operating Income for the three months ended in Dec. 2025 was €-15.11 Mil. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Interest Expense for the three months ended in Dec. 2025 was €-0.02 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Interest Coverage or its related term are showing as below:


FRA:FDY's Interest Coverage is not ranked *
in the Drug Manufacturers industry.
Industry Median: 12.78
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co  (FRA:FDY) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Interest Coverage Related Terms


Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Interest Coverage Historical Data

* Premium members only.

The historical data trend for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Interest Coverage Chart

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Coverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only 179.83 80.96 42.36 8.35 0.00

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Quarterly Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Jun25 Sep25 Dec25
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 N/A 0.00 0.00

FRA:FDY vs ZTS: Interest Coverage Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Interest Coverage vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Interest Coverage falls into.


FRA:FDY
72GF Score
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd FRA:FDY
Interest Coverage is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Interest Coverage for the fiscal year that ended in Dec. 2025 is calculated as

Here, for the fiscal year that ended in Dec. 2025, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Interest Expense was €-0.08 Mil. Its Operating Income was €-20.66 Mil. And its Long-Term Debt & Capital Lease Obligation was €1.13 Mil.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co did not have earnings to cover the interest expense.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Interest Coverage for the quarter that ended in Dec. 2025 is calculated as

Here, for the three months ended in Dec. 2025, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Interest Expense was €-0.02 Mil. Its Operating Income was €-15.11 Mil. And its Long-Term Debt & Capital Lease Obligation was €1.13 Mil.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.

Frequently Asked Questions Learn more about Interest Coverage →
What does a Interest Coverage of 0 (At Loss) mean?
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (FRA:FDY) has a Interest Coverage of 0 (At Loss) as of Dec. 2025. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co and its competitors. According to the industry distribution chart, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co ranks #999999 out of 685 companies in the Drug Manufacturers industry.
Is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Interest Coverage too high?
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's current Interest Coverage is 0 (At Loss). Based on the distribution chart, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co ranks #999999 out of 685 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co has a GF Score™ of 72/100, reflecting its overall financial health beyond just this single metric.
How does Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Interest Coverage compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co ranks #999999 out of 685 companies for Interest Coverage. This places Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co in the lower half of its industry. The industry median Interest Coverage is 12.78. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.78, based on 685 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's current Interest Coverage is 0 (At Loss). However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co stock overvalued right now?
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (FRA:FDY) has a current Interest Coverage of 0 (At Loss). The stock's GF Value™ is €0.24, compared to a current price of €0.25 — trading 3.3% above its estimated fair value. The current Interest Coverage is 0 (At Loss). Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's overall GF Score™ is 72/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (FRA:FDY), the current Interest Coverage is 0 (At Loss) as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (FRA:FDY) Overvalued in 2026?

Based on GuruFocus' analysis, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co stock appears to be overvalued. The current stock price of €0.25 is trading 3.3% above its estimated GF Value™ of €0.24.

Key valuation signals for FRA:FDY:

  • Interest Coverage: 0 (At Loss)
  • GF Value™: €0.24 vs. price of €0.25 (3.3% above fair value)
  • GF Score™: 72/100 with 2 warning signs

No single metric tells the full story. See the FRA:FDY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Business Description

Other Exchanges 01349:Hong Kong688505:China
Address 308 Cailun Road, Zhangjiang Hi-Tech Park, Pudong, Shanghai, CHN, 201210
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd is engaged in the research, development, manufacturing, and sale of biopharmaceutical products. Its product portfolio includes ALA (Aminolevulinic acid Hydrochloride); FuMeiDa and Libord. The company has launched it's four types of photodynamic drugs in China market, namely hematoporphyrin, aminolevulinic acid hydrochloride, Verteporfin and Hemoporfin. Geographically, it derives revenue from Mainland China.
72GF Score

Get the complete analysis for FRA:FDY

Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.25
Price
€0.24
GF Value